January 2026—The FDA has approved the Promega OncoMate MSI Dx analysis system as a companion diagnostic designed to identify patients with microsatellite stable (defined as not MSI-high) endometrial carcinoma who may benefit from treatment with pembrolizumab (Keytruda, Merck) plus lenvatinib (Lenvima, Eisai). OncoMate MSI Dx is a PCR-based assay designed to evaluate MSI status in tumor tissue.
Promega, 608-274-4330